SPACE and EVA-3S are the latest to publish outcomes in recently symptomatic patients who were randomised to carotid endarterectomy (CEA) or angioplasty and stenting (CAS). Contrary to expectations, both found that CAS was not 'as good as' CEA, while EVA-3S found CEA to be statistically superior. Not surprisingly, these trials have aroused considerable controversy and many in the pro-CAS lobby have simply dismissed them as being methodologically flawed and unrepresentative of contemporary CAS practice. However, to simply dismiss SPACE and EVA-3S as maverick trials is unacceptable. Unlike the landmark 'symptomatic' and 'asymptomatic' studies, the history of randomised trials comparing CAS and CEA has been characterised by repeated trial suspension (because of excess risk in the CAs cohort) and a systematic failure to achieve randomisation targets (thereby preventing any prospect of a statiscally meaningful outcome) amid a milieu of corporate and individual conflicts of interest. SPACE and EVA-3S have certainly informed the dabate but they have not resolved it. Two trials are actively randomising recently symptomatic patients (ICSS in Europe and CREST in North America). Both require our support so that future guidelines are 'evidence based' rather than 'marker driven'.
Laparoscopic cholecystectomy is a classic example of how a new technique replaced a 'gold-standard' without resorting to multi-centre, randomised trials. By contrast, the longevity of carotid endarterectomy (CEA) is exclusively due to it having been subjected to detailed randomised comparison, despite surgical opposition at the time. Four trials (ECST, NASCET, ACAS & ACST) were pivotal in determining who gained most (and least) from CEA.
1e4 Most importantly, these guidelines were achieved with remarkable consensus amongst surgeons, neurologists and stroke physicians.
Unfortunately, eight randomised trials comparing CEA with angioplasty and stenting (CAS) have failed to establish any consensus. 5e12 More worrying, this failure to provide an unambiguous answer to a seemingly simple question has fuelled a belief that randomised trials may never provide a definitive answer coincidental with an environment of corporate/individual conflicts of interest, interdisciplinary turf-wars and the effect of a surgeon worrying about his/her income.
These are, of course, provocative comments! WALLSTENT, one of the largest randomised trials of its era was industry sponsored. When abandoned, with a threefold excess risk after CAS, it only reported in abstract form. 6 One is left to assume that the sponsors blocked its publication. Second are the sequellae of SAPPHIRE, 12 another industry sponsored trial in predominantly asymptomatic patients that influenced 'opinion' more than its findings warranted. 13 The first consequence was declining recruitment into other randomised trials as commentators hailed CAS as the 'safer' or 'preferred' option.
14 Thereafter, rivals realised that one company was going to dominate the market and so the SAPPHIRE findings were used to justify a myriad of 'high-risk' stent registries in order to promote rival stents and cerebral protection devices (CPD). This 'market-driven' swing towards CAS then caused some surgeons to fear that their income might be threatened. It was then inevitable that the surgeon would also become a CAS expert and join the 'turf-war' with cardiologists, neuroradiologists 15 Although SAPPHIRE may remain 'whiter than white', this is not the way to determine evidence based practice.
Given this background, it was inevitable that publication of SPACE and EVA-3S would court controversy as the findings were clearly at odds with the trend towards CAS. 9, 10 Using predefined margins of non-inferiority, both showed that CAS was not 'as good as' CEA, while EVA-3S found that CEA was statistically superior. Accordingly, CEA secured temporary respite while the pro-CAS lobby responded with a campaign of 'damage limitation' with particular anger being focussed on 'interventionist experience' and 'CAS methods' in the two trials. Ironically, this strategy of 'discrediting the opposition' had been honed to perfection by surgeons two decades earlier when the primacy of CEA was questioned! Do we never learn?
So where to now? If CAVATAS answered nothing else, it demonstrated to a sceptical surgical audience that following successful CAS, three year outcomes were probably no different to CEA. 7 Accordingly, the intervention which wins the battle of the '30-day risk' will triumph in the end. Table 1 summarises data from the six randomised trials in recently symptomatic patients. With few exceptions, each reported 30-day risks that were well in excess of those being reported in the non-randomised literature. Second, four of six trials failed to achieve their planned recruitment (by a staggering 1803 patients in total) thereby compromising any realistic chance of securing statistically valid outcomes. Third, is the very real difficulty of comparing outcomes as CAS technology evolves (e.g. publication year, learning curve, CPD, dual antiplatelet therapy).
EVA-3S faces the most hostile criticism regarding the third observation. Yet, paradoxically, EVA-3S may represent what could happen in the 'real world' following implementation of CAS into routine practice, rather than seeing what happens in 'elite' CAS units. Déjà vu! The same criticism (regarding generalisability) was levelled by neurologists in the 1990s when surgeons were faced with the accusation that their high-quality trial results simply reflected surgeon selection. To-date, CAS practitioners have never had to address the issue of generalisability. Moreover, CPDs are clearly no panacea as evidenced by the SPACE and EVA-3S findings of a 30-day death/stroke rate of 7% when they were used. EVA-3S (like SPACE) used proctoring, but neither the number of patients randomised per centre, nor the previous 'experience' of the CAS practitioner influenced outcome. Similarly, dual antiplatelet therapy did not influence risk, nor did whether the patient was randomised pre February 2003 (when EVA-3S was suspended and restarted with obligatory CPD usage) or after February 2003.
These observations will, of course, never satisfy the ardent critic who will counter that he/she can perform CAS with 30-day death/stroke rates of 2e3% or less. Not surprisingly, many surgeons make similar claims regarding their own CEA practice. That is not the point! It would however be interesting to know how many of these critics participated in PASCAL (another industry sponsored stent registry using experienced CAS interventionists) and which encountered a 30-day death/stroke rate of 7.5% in asymptomatic patients! Funnily enough, that registry hasn't published either!
In conclusion, surgeons who think that SPACE and EVA-3S have settled the debate and restored CEA to primacy are deluded! Similarly, those interventionists who comfort themselves by writing off SPACE and EVA-3S as maverick trials are also blind to reality. The most obvious reason why the results of SPACE and EVA-3S were poorer than SAPPHIRE is that they randomised recently symptomatic patients, i.e. high risk for stroke. That description could never apply to the SAPPHIRE cohort. Finally, the main reason why ECST, NASCET, ACAS and ACST influenced clinical practice was because they randomised large numbers of patients. CEA and CAS will inevitably have a complementary role. It is therefore imperative that we support the two remaining trials that are randomising recently symptomatic patients (ICSS in Europe and CREST in North America).
One day it may be you who will benefit from the best available evidence! 4 Asymptomatic Carotid Surgery Trial Collaborators. The MRC
